Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Current Assets (2019 - 2025)

Vivos Therapeutics has reported Current Assets over the past 7 years, most recently at $4.4 million for Q4 2025.

  • Quarterly Current Assets fell 41.34% to $4.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.4 million through Dec 2025, down 41.34% year-over-year, with the annual reading at $4.4 million for FY2025, 41.34% down from the prior year.
  • Current Assets was $4.4 million for Q4 2025 at Vivos Therapeutics, down from $5.8 million in the prior quarter.
  • Over five years, Current Assets peaked at $39.4 million in Q2 2021 and troughed at $2.0 million in Q3 2023.
  • The 5-year median for Current Assets is $7.4 million (2024), against an average of $11.8 million.
  • Year-over-year, Current Assets plummeted 80.15% in 2022 and then soared 272.75% in 2024.
  • A 5-year view of Current Assets shows it stood at $27.3 million in 2021, then plummeted by 80.15% to $5.4 million in 2022, then crashed by 54.63% to $2.5 million in 2023, then surged by 203.66% to $7.5 million in 2024, then crashed by 41.34% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Current Assets are $4.4 million (Q4 2025), $5.8 million (Q3 2025), and $6.7 million (Q2 2025).